Ocular Allergy Treatment Practical Impact Trial

To Assess the Impact of Ocular Allergy Treatment on Patients Using an Opthalmic Agent (or no Treatment) Versus Alcaftadine(Lastacaft™)

To study the impact of alcaftadine in patients treated with other opthalmic ocular agents (or specific topical opthalmic treatment) in an allergy subspecialist outpatient setting.

To assess the impact of ocular allergy treatment on patients using an ophthalmic agent (or no treatment) versus alcaftadine(Lastacaft™)

Inclusion Criteria:

1. patients age 18 and older with a history of seasonal or perennial forms of allergic conjunctivitis and skin test positive reactivity to seasonal aeroallergens

2. Total Ocular Symptom Score (TOSS) on the day of enrollment of 4 or more.

3. have allergic ocular symptoms for the past week for which they are either treating with ophthalmic agents or have had no treatment.

4. Are willing/able to follow instructions from the study investigator and his/her study staff.

5. Have signed infromed consent approved by Institutional Review Board or Independent Ethics Committee.

   -

Exclusion Criteria:

1. Active ocular infection;
2. History of retinal detachment, diabetic neuropathy, or any progressive retinal disease;
3. Ocular surgical intervention within three (3) months prior to visit 1 or scheduled during the study.
4. History of unstable, or uncontrolled disease of any nature.
5. Pregnancy or lactation;
6. Have a known hypersensitivity tp LASTACAFT™ (alcaftadine) -